Cabotegravir plus rilpivirine - Janssen Therapeutics/ViiV Healthcare

Drug Profile

Cabotegravir plus rilpivirine - Janssen Therapeutics/ViiV Healthcare

Alternative Names: CAB LA + RPV LA combination therapy; Cabotegravir plus rilpivirine combination therapy; GSK 1265744 plus rilpivirine combination therapy; GSK 1265744 plus TMC 278 combination therapy; Long-acting cabotegravir plus long-acting rilpivirine combination therapy

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceuticals; ViiV Healthcare
  • Developer GlaxoSmithKline; Janssen Pharmaceuticals; ViiV Healthcare
  • Class Fluorobenzenes; Nitriles; Oxazoles; Pyrazines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 27 Oct 2017 ViiV Healthcare initiates enrolment in a phase III ATLAS-2M trial in HIV infections (Combination therapy, Treatment-experienced, Treatment naive) in Spain (PO) (IM) (NCT03299049)
  • 24 Jul 2017 Updated adverse events data from a phase II trial in HIV infections released by Janssen Sciences
  • 24 Jul 2017 Updated efficacy data from the phase II LATTE-2 trial in HIV-1 infections released by ViiV Healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top